Hookipa Pharma (NASDAQ:HOOK) Receives Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a report released on Monday, Benzinga reports. They currently have a $6.50 price objective on the stock. Separately, Royal Bank of Canada reduced their target price on Hookipa Pharma from $6.00 to $5.00 and set an outperform rating on […]
More Stories
Restaurant Fit-Out Planning Tips for Comfort, Flow and Durability
A restaurant fit-out is really juggling two jobs at the same time. It has to make guests feel like they’ve...
How to Choose the Perfect Dining Table for Your Home Layout
A dining table ends up being more than a table, doesn’t it. Meals happen there, sure, but that’s barely the...
What is Snapchat Planet Order? Meaning, Origin, and More Details
Snapchat is one of the most widely used social media platforms. It stands neck to neck with other popular social...
Is The Amazing Digital Circus Renewed? Know about its Release Date
Are you also a fan of adult anime shows? Good news, everyone’s favourite fantasy drama, The Amazing Digital Circus, aka...
Tex Mex Motors Season 3 Updates and Renewal Details
The 2023 premiere series, Tex Mex Motors, is a reality TV show. The series has 2 seasons with episodes showing...
Grown Ups 3: Release Date, Cast Members, and Trailer Updates
About 16 years after its release, the comedy film Grown Ups is finally getting a sequel. The famous group of...